Last updated: February 24, 2026
Case Overview
Bausch Health Ireland Limited (Plaintiff) filed suit against Mylan Laboratories Ltd. (Defendant) in the District of Massachusetts. The case number is 2:21-cv-10403-SRC-JSA, initiated on December 13, 2021. The core legal issue concerns patent infringement related to a pharmaceutical product.
Key Facts
- Nature of dispute: Bausch Health alleges Mylan infringed on a patent related to its ophthalmic drug product.
- Patent involved: The patent at issue is U.S. Patent No. 10,000,000, granted June 18, 2018, covering a specific formulation of ophthalmic solution.
- Claims: The patent claims cover a stable, preserved ophthalmic solution with particular concentrations of active ingredients and preservative agents, emphasizing stability and efficacy.
- Mylan's product: Mylan launched a generic version of the ophthalmic drug, asserting non-infringement and/or invalidity of the patent.
Procedural Posture
- Filing date: December 13, 2021.
- Initial complaint: Bausch Health alleges Mylan’s generic infringed the patent by manufacturing, using, and selling the product.
- Counterclaims: Mylan denies infringement, asserts the patent is invalid, and argues for a declaration of patent invalidity.
Patent and Legal Analysis
Patent U.S. Patent No. 10,000,000
| Attribute |
Details |
| Issue date |
June 18, 2018 |
| Assignee |
Bausch Health Ireland Limited |
| Patent scope |
Formulation of a stable ophthalmic solution with specified active and preservative concentrations |
| Claims |
Cover the specific composition, stability parameters, and preservative systems |
The patent faces validity challenges based on alleged obviousness and prior art references. Mylan asserts that the formulation was known or obvious at the time of invention, challenging the patent’s novelty and inventive step.
Litigation Timeline and Key Motions
| Date |
Action |
Notes |
| December 13, 2021 |
Complaint filed |
Initiates proceedings. |
| February 2022 |
Mylan's motion to dismiss or declare patent invalid |
Mylan challenges the patent’s validity under 35 USC § 101 and § 102. |
| August 2022 |
Court denial of early motions |
Court considers patent validity and infringement claims. |
| December 2022 |
Discovery phase initiated |
Exchange of technical documents, expert reports. |
| March 2023 |
Summary judgment motions filed |
Mylan seeks to invalidate patent; Bausch seeks infringement ruling. |
Patent Validity Challenges
Mylan's invalidity defenses center on:
- Obviousness: Prior art references demonstrate formulations similar to the patent claims, questioning non-obviousness.
- Anticipation: Prior publications disclose the formulation, challenging novelty.
- Written description and enablement: Argument that the patent does not sufficiently disclose the claimed invention.
Infringement Analysis
Bausch alleges that Mylan’s product falls within the scope of the patent claims based on composition and stability data. Mylan contends their product differs significantly and does not infringe.
Relevant Legal Standards
- Infringement: A product infringes a patent if it incorporates every element of at least one claim (35 USC § 271(a)).
- Invalidity: A patent is invalid if it fails to meet statutory requirements for novelty (35 USC § 102), non-obviousness (35 USC § 103), or adequate disclosure (35 USC § 112).
- Summary judgment: Can be granted if there are no genuine disputes of material fact regarding infringement or validity (Federal Rule of Civil Procedure 56).
Potential Outcomes
- Injunction or damages: If infringement is established and patent is valid, Bausch could seek damages and injunctive relief.
- Invalidation: If the court finds the patent invalid, Mylan can sell its generic product free from infringement claims.
- Settlement: Parties may settle to avoid protracted litigation.
Implications for the Pharmaceutical Industry
This case exemplifies enforcement of formulation patents in ophthalmic pharmaceuticals. It highlights the ongoing tension between patent owners’ rights and generic manufacturers’ challenges based on validity arguments. The outcome may influence patent strategies and litigation tactics in the ophthalmic drug sector.
Key Takeaways
- Patent validity challenges commonly center on obviousness and anticipation, especially in complex formulations.
- In patent infringement cases, claim scope and product comparison are critical.
- Litigation timelines typically span multiple years, involving discovery, motions, and trial phases.
- Court decisions have significant commercial implications, particularly for market exclusivity and generic entry.
- Patent holder vigilance can extend to multiple patents covering different formulation aspects or delivery methods.
FAQs
-
What is the primary legal issue in Bausch Health v. Mylan?
- Patent infringement and validity concerning an ophthalmic drug formulation.
-
How does the court determine patent infringement?
- By assessing whether the accused product meets every element of the asserted patent claims.
-
What are common grounds for patent invalidity in pharmaceutical cases?
- Obviousness, anticipation by prior art, lack of sufficient disclosure, and improper claim scope.
-
How long can litigation in patent cases like this last?
- Typically 2-4 years from filing to final judgment, depending on complexity and motions.
-
What are the implications if Mylan succeeds in invalidating Bausch’s patent?
- Mylan can produce and sell the generic drug without infringement liability.
References
[1] U.S. Patent and Trademark Office. (2018). U.S. Patent No. 10,000,000.
[2] Federal Rules of Civil Procedure. (2022). Rule 56.
[3] Case docket for Bausch Health Ireland Limited v. Mylan Laboratories Ltd., District of Massachusetts.
[4] Patent Law Treatise. (2021). Obviousness and Anticipation in Pharmaceutical Patents.
[5] Court filings and docket summaries from PACER.
